: CPG031010 TIME :10-08-'20 10:04 F/W Ver. : T470SY0A210 M-ROM Ver. : 470M-15 S-ROM Ver. : 470S-03 **GENERAL** Tanta Counter University 216200 Facultraufr Medicine A4-R Clinical Oncology Department : A4 45 9/11/2021 COPTime allowed: 3 Hours **EXPOSURE** MD Exam AUTO ORIGINAL MODE FOR BLACK Clinical Oncology & Nuclear Medicine IMAGE DIRECTION ChemotherapyIN BYPASS FEED All Questions should be answered: Marks 1- Cardiovascular toxicity with anticancer treatments is a major problem. a- Innumerate the top list of drug causes this problem? 20 b- What is its mechanism that causes this damage? 20 20 c- Describe management and prevention? 2- Innumerate risks and benefits associated with gastrostomy tubes for patients with cancer? 30 3- Explain in detail obesity with cancer? 30 4- When you decide to treat actively cancer patient with impending cholemia? 40 5- Molecular management of advanced urothelial cancer? 40 6- Intertwined dilemma in the management of advanced HCC? 40 7- Management of cold tumors? 30 45 8- Management of adrenocortical malignant tumors? 9- The pronounced role of chimeric antigen receptor T cell therapy

(CAR T-cell therapy) in cancer management?

45

FUNCTION LIST

Tanta University
Faculty of Medicine
Clinical Oncology Department

30/10/2021

Time allowed: 3 Hours

MD Exam Clinical Oncology & Nuclear Medicine RADIATION THERAPY

All Questions should be answered:

Marks

- 1- Dose fractionation effects are utilized in the treatment of cancer with radiation therapy.
- a- What is the role of reoxygenation with fractionated radiation therapy in clinical practice?30
- **b-** Hypo fractionated irradiation and immune modulation therapies: can they work together? Explore? 30
- 2- Treatment of head and neck cancer may include a combination of surgery, radiation therapy, chemotherapy, and targeted therapy.
- a- Describe patient-reported toxicity and quality-of-life profiles in patients with head and neck cancer treated with definitive radiation therapy or chemoradiation?
 30
- b- What is the mechanism, diagnosis, and management of osteoradionecrosis (ORN) after radiation therapy for head and neck carcinomas?
- 3- Radiation therapy is often integrated in the management of prostate cancer.
 - a- Discuss conventionally fractionated volumetric arc therapy versus hypo fractionated stereotactic body radiotherapy: as regard side effects, and prostate-specific antigen kinetics in localized prostate cancer?
 30
 - b- Elective nodal radiotherapy for prostate cancer: for none, some, or all?

 Discuss.

 30

- 4- A 49-years-old male was admitted to the hospital with a flank pain. His workup included abdominopelvic CT and MRI, which showed an 18 × 12 × 11-cm left-sided retroperitoneal mass adherent to the ureter and invading the psoas muscle without any suspicious nodal disease. Interventional radiology with a true-cut biopsy showed soft tissue sarcoma, probably leiomyosarcoma, of high grade. Thorax CT showed no pulmonary metastasis. What are the treatment recommendations? 40
- 5- Explain in detail the role of Gallium-labelled in cancer diagnosis and management?
- 6- Primary Mediastinal B-Cell Lymphoma: Discuss challenges in the role of consolidative radiation for a "Terrible" Lymphoma histological types?
- 7- Hot spots in radiotherapy plans have been described as creating "double trouble" by providing a higher total dose and delivering it at a higher dose/ fraction:- Describe how these two events acts independently to increase the risk of treatment toxicity?
 50